MPM

Targovax granted European Patent for ONCOS-102 in combination with chemotherapy

Retrieved on: 
Friday, September 24, 2021
Patent, Mesothelioma, SOC, European Patent Convention, Unitary patent, MPM, OSE, European Medicines Agency, Patient, Population, Immune system, MOS, Survival, Safety, European Patent Office, US, Pharmaceutical industry

OSLO, Norway, Sept. 24, 2021 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announce that the European Patent Office has granted EU Patent no EP3402889. The patent covers the use of ONCOS-102 in combination with chemotherapy in malignant pleural mesothelioma.

Key Points: 
  • OSLO, Norway, Sept. 24, 2021 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announce that the European Patent Office has granted EU Patent no EP3402889.
  • The patent covers the use of ONCOS-102 in combination with chemotherapy in malignant pleural mesothelioma.
  • Torbjrn Furuseth, Chief Financial Officer of Targovax, said: "We are delighted that this EU patent has been granted, further strengthening Targovax's intellectual property portfolio.
  • Targovax has previously received orphan drug designation for MPM in both the US FDA and the European Medicines Agency.

Targovax granted European Patent for ONCOS-102 in combination with chemotherapy

Retrieved on: 
Friday, September 24, 2021
Patent, Mesothelioma, SOC, European Patent Convention, Unitary patent, MPM, OSE, European Medicines Agency, Patient, Population, Immune system, MOS, Survival, Safety, European Patent Office, US, Pharmaceutical industry

OSLO, Norway, Sept. 24, 2021 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announce that the European Patent Office has granted EU Patent no EP3402889.

Key Points: 
  • OSLO, Norway, Sept. 24, 2021 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announce that the European Patent Office has granted EU Patent no EP3402889.
  • The patent covers the use of ONCOS-102 in combination with chemotherapy in malignant pleural mesothelioma.
  • Torbjrn Furuseth, Chief Financial Officer of Targovax, said: "We are delighted that this EU patent has been granted, further strengthening Targovax's intellectual property portfolio.
  • Targovax has previously received orphan drug designation for MPM in both the US FDA and the European Medicines Agency.

MPM Strengthens its Team with the Addition of Accomplished Biotech Executive and Drug Discoverer Wendy Young, PhD

Retrieved on: 
Thursday, September 23, 2021
Other Professional Services, Biotechnology, Finance, Health, Consulting, Banking, Professional Services, Other Health, Molecule, Biotechnology, MPM, ACS, Medicinal chemistry, Eli Lilly, Woman, Celera Corporation, Patient, Chemistry, Genentech, Lung cancer, Princeton University, Leadership, Medicine, Journal of Medicinal Chemistry, Science, Technology, Journal, Research, Drug development, Drug discovery, R, Laboratory, Doctor of Philosophy, SVP, Multiple sclerosis, Breast cancer, Memorial Sloan Kettering Cancer Center, Pharmaceutical industry

MPM, a world-leading biotechnology investment firm with nearly three decades of experience creating and investing in early-stage therapeutics companies, today announced the recent appointment of leading biotech executive and drug discoverer Wendy Young, PhD, to its team of accomplished Executive Partners.

Key Points: 
  • MPM, a world-leading biotechnology investment firm with nearly three decades of experience creating and investing in early-stage therapeutics companies, today announced the recent appointment of leading biotech executive and drug discoverer Wendy Young, PhD, to its team of accomplished Executive Partners.
  • At Genentech, Wendy led research activities and oversaw 900 internal and external multi-disciplinary scientists engaged in drug discovery.
  • Earlier in her career, Wendy held drug discovery roles at SCIOS, a Johnson & Johnson Company, and Celera Genomics.
  • Were delighted that Wendy has joined our senior team of MPM Entrepreneurs, said Ed Hurwitz, Managing Director, MPM Capital.

MPM Expands its Team with the Appointment of RNA Expert and Leading Biotech Executive Pete Smith, PhD

Retrieved on: 
Tuesday, September 21, 2021
Professional Services, Oncology, Health, Finance, Pharmaceutical, Biotechnology, Biotechnology, Infection, RNA transfection, MPM, Partner (business rank), RNA, Head, Therapy, Inflammation, GlaxoSmithKline, Central nervous system, Merck, Sirna, Pharmacia, Drug development, Drug discovery, Doctor of Philosophy, Millennium, SVP, Industry, Pharmaceutical industry

MPM, a world-leading biotechnology investment firm with nearly three decades of experience creating and investing in early-stage therapeutics companies, today announced the recent appointment of leading biotech executive Pete Smith, PhD, to its team of MPM Entrepreneurs.

Key Points: 
  • MPM, a world-leading biotechnology investment firm with nearly three decades of experience creating and investing in early-stage therapeutics companies, today announced the recent appointment of leading biotech executive Pete Smith, PhD, to its team of MPM Entrepreneurs.
  • Pete brings a wealth of experience to MPM having spent more than thirty years in the pharmaceutical industry, including thirteen years at Millennium.
  • He brings extensive and proven experience in building and leading teams spanning discovery through development across multiple modalities.
  • At MPM, Pete will take a leading role in helping the team explore new opportunities, particularly in those in areas of new modalities, including RNA therapies.

New Survey Finds Marketers Are Still Struggling to Measure ROI

Retrieved on: 
Thursday, August 26, 2021
Marketing, Communications, Professional Services, Other Professional Services, Other Communications, Marketing, Language, Organization, Juniper Networks, MPM, Customer success, Autodesk, Land, Pressure, ROI, Solution, Risk management, Sales

Unfortunately, many are struggling to effectively measure this ROI.

Key Points: 
  • Unfortunately, many are struggling to effectively measure this ROI.
  • The survey found that 61% of marketing leaders do not use ROI when making strategy decisions because they arent confident in their own data.
  • Another key finding highlighted in the survey is an inability for many organizations to agree on a definition and measurement of marketing ROI.
  • Thankfully, strategies and solutions exist that empower marketers to understand their ROI and make better decisions to support company growth.

SELLAS Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 12, 2021
PD-1, Blood, USPTO, Clinical trial, WT1, MPM, SLS, TNBC, Patent, Memorial Sloan Kettering Cancer Center, Growth, Progression-free survival, Union, Merck Sharp & Dohme Federal Credit Union, Doctor of Science, Immunotherapy, NPS, Time, MRD, Company, Hematopoietic stem cell transplantation, Pembrolizumab, SEC, D, Merck & Co., Annual report, Technology transfer, Cancer, Baylor University Medical Center, CR1, Standard of care, Lymphatic system, MD, Nivolumab, COVID-19, DCR, Ovarian cancer, NEW, Position, Merck, HER2, NASDAQ, Pemetrexed, Terminology, Research, Bristol Myers Squibb, Drug development, OS, Probability, Survival, Russell, GLOBE, Acquisition, Patient, European Union, Second, PFS, Diagnosis, GPS, AML, Corporation, Cryptocurrency, Pharmaceutical industry, Dentistry

NEW YORK, Aug. 12, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today reported its financial results for the quarter ended June 30, 2021 and provided a business update.

Key Points: 
  • (NASDAQ: SLS) ("SELLAS" or the Company), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today reported its financial results for the quarter ended June 30, 2021 and provided a business update.
  • Financial Results for the Second Quarter 2021:
    Licensing revenue: Licensing revenue was $1.9 million for the second quarter of 2021 and $7.6 million for the first half of 2021 which consists of the recognition of revenue from the Companys license agreement with 3D Medicines.
  • R&D Expenses: Research and development expenses for the second quarter of 2021 were $3.5 million, as compared to $2.3 million for the same period in 2020.
  • About SELLAS Life Sciences Group, Inc.
    SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of indications.

MPM Capital Adds to Senior Team with the Appointment of Oncology Leader Pankaj Bhargava, MD as Executive Partner

Retrieved on: 
Tuesday, April 13, 2021
Professional services, Oncology, Health, Finance, Pharmaceutical, Biotechnology, MPM

b"MPM Capital (MPM), a biotechnology investment firm investing in early-stage therapeutics companies, today announced that Pankaj Bhargava, MD has joined its team of Executive Partners.\n\xe2\x80\x9cWe are delighted to welcome Pankaj to the MPM team,\xe2\x80\x9d said Ansbert Gadicke, co-founder and managing director, MPM Capital.

Key Points: 
  • b"MPM Capital (MPM), a biotechnology investment firm investing in early-stage therapeutics companies, today announced that Pankaj Bhargava, MD has joined its team of Executive Partners.\n\xe2\x80\x9cWe are delighted to welcome Pankaj to the MPM team,\xe2\x80\x9d said Ansbert Gadicke, co-founder and managing director, MPM Capital.
  • \xe2\x80\x9cHaving worked with MPM on business development initiatives while at Gilead and interfacing directly with the firm\xe2\x80\x99s senior team, I saw first-hand the scientific rigor, expertise, and creativity that has made MPM so successful.
  • from the University of Delhi and completed his training in medical oncology and developmental therapeutics at Georgetown University and Lombardi Cancer Center.
  • With its experienced and dedicated team of investment professionals, entrepreneurs, and advisors, MPM strives to power novel medical breakthroughs that transform patients' lives.

MPM Capital Strengthens Team with the Addition of Neuroscience R&D Leader David S. Bredt, MD, PhD as Executive Partner

Retrieved on: 
Wednesday, April 7, 2021
Health, Clinical trials, Research, Pharmaceutical, Science, Biotechnology, Bredt, MPM

MPM Capital (MPM), a leading biotechnology investment firm investing in early-stage therapeutics companies, today announced that David S. Bredt, MD, PhD, has joined its team of Executive Partners.

Key Points: 
  • MPM Capital (MPM), a leading biotechnology investment firm investing in early-stage therapeutics companies, today announced that David S. Bredt, MD, PhD, has joined its team of Executive Partners.
  • David will take a leading role in helping MPM explore a range of opportunities, including those presented by new developments in the understanding of neurological dysfunction.
  • I am thrilled to join MPM Capital and to bring leadership in both drug discovery and the field of neurology to this accomplished team, said Dr. Bredt.
  • With its experienced and dedicated team of investment professionals, entrepreneurs, and advisors, MPM strives to power novel medical breakthroughs that transform patients' lives.

Global Malignant Pleural Mesothelioma (MPM) Pipeline Insights Report 2020: MTG201, YS110, Poly-ICLC (Hiltonol) Vaccine, rAd-IFN, Nivolumab and ipilimumab, ONCOS-102 - ResearchAndMarkets.com

Retrieved on: 
Friday, February 5, 2021
Health, Pharmaceutical, Occupational diseases, Torso, Asbestos, Mesothelioma, Organ systems, Pleural cavity, Cancer, MPM, Malignant pleural effusion

This "Malignant Pleural Mesothelioma (MPM) - Pipeline Insight, 2020," report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Malignant Pleural Mesothelioma pipeline landscape.

Key Points: 
  • This "Malignant Pleural Mesothelioma (MPM) - Pipeline Insight, 2020," report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Malignant Pleural Mesothelioma pipeline landscape.
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Malignant Pleural Mesothelioma?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Malignant Pleural Mesothelioma therapeutics?
  • What are the clinical studies going on for Malignant Pleural Mesothelioma and their status?

FDA Approves Drug Combination for Treating Mesothelioma

Retrieved on: 
Friday, October 2, 2020
Health, RTT, Neoplasms, Occupational diseases, Mesothelioma, Pemetrexed, MPM, Asbestos, Cancer, Mesomark assay, Asbestos-related diseases

This is the first drug regimen approved for mesothelioma in 16 years and the second FDA-approved systemic therapy for mesothelioma.

Key Points: 
  • This is the first drug regimen approved for mesothelioma in 16 years and the second FDA-approved systemic therapy for mesothelioma.
  • "In 2004, FDA approved pemetrexed in combination with cisplatin for this indication, and now patients now have an important, additional treatment option after more than a decade with only one FDA-approved drug regimen."
  • Malignant pleural mesothelioma (MPM) is a life-threatening cancer of the lungs' lining caused by inhaling asbestos fibers that about 20,000 Americans are diagnosed with each year.
  • MPM accounts for most mesothelioma diagnoses, and most patients have an unresectable (unable to be removed with surgery) tumor at time of diagnosis.